The DOI matches its Crossref record; 250 of the 250 references it cites were found in a registry or an index.
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–250 of 250
Structural basis for oligoclonal T cell recognition of a shared p53 cancer neoantigen
Wu, D., Gallagher, D. T., Gowthaman, R., Pierce, B. G., & Mariuzza, R. A. (2020) · Nature Communications · doi:10.1038/s41467-020-16755-y · Cited by 78
Babačić, H., Lehtiö, J., de Coaña, Y. P., Pernemalm, M., & Eriksson, H. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000204 · Cited by 75
Park, K. J., Lee, J., Yoon, S., Heo, C., Park, B. W., & Kim, J. K. (2020) · European Radiology · doi:10.1007/s00330-020-06847-0 · Cited by 72
Liu, Y., Wu, M., Zhang, Y., Luo, Y., He, S., Wang, Y., Chen, F., Liu, Y., Yang, Q., Li, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.657615 · Cited by 72
Nardone, V., Tini, P., Pastina, P., Botta, C., Reginelli, A., Carbone, S. F., Giannicola, R., Calabrese, G., Tebala, C., Guida, C., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.11220 · Cited by 70
Structural dissimilarity from self drives neoepitope escape from immune tolerance
Devlin, J. R., Alonso, J. A., Ayres, C. M., Keller, G. L. J., Bobisse, S., Kooi, C. W. V., Coukos, G., Gfeller, D., Harari, A., & Baker, B. M. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0610-1 · Cited by 70
Valentinuzzi, D., Vrankar, M., Boc, N., Ahac, V., Zupancic, Z., Unk, M., Škalic, K., Žagar, I., Studen, A., Simončič, U., et al. (2020) · Radiology and Oncology · doi:10.2478/raon-2020-0042 · Cited by 69
A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC
Pan, D., Hu, A. Y., Antonia, S. J., & Li, C. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.021 · Cited by 68
Wu, H., Zheng, X., Pan, T., Yang, X., Chen, X., Zhang, B., Peng, L., & Xie, C. (2022) · International Journal of Cancer · doi:10.1002/ijc.34118 · Cited by 65
Bhatia, A., Birger, M. L., Veeraraghavan, H., Um, H., Tixier, F., McKenney, A. S., Cugliari, M. K., Caviasco, A., Bialczak, A., Malani, R., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz141 · Cited by 64
Fessas, P., Naeem, M., Pinter, M., et al. (2021) · Liver Cancer · doi:10.1159/000519108 · Cited by 63
Jiang, Y., Turinsky, A. L., & Brudno, M. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv677 · Cited by 61
Yoon, H. J., Kang, J. K., Park, H., Sohn, I., Lee, S.-H., & Lee, H. Y. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231227 · Cited by 61
Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease
Mittendorf, E. A., Burgers, F. H., Haanen, J. B. A. G., & Cascone, T. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349411 · Cited by 61
Shi, A., Kasumova, G. G., Michaud, W. A., Cintolo-Gonzalez, J., Díaz‐Martínez, M., Ohmura, J. F., Mehta, A., Chien, I., Frederick, D. T., Cohen, S., et al. (2020) · Science Advances · doi:10.1126/sciadv.abb3461 · Cited by 60
Self-citationHofmann, S., Cohen-Harazi, R., Maizels, Y., & Koman, I. E. (2021) · Translational Cancer Research · doi:10.21037/tcr-21-1577 · Cited by 56
Tunali, I., Tan, Y. Q., Gray, J. E., Katsoulakis, E., Eschrich, S. A., Saller, J. J., Aerts, H. J. W. L., Boyle, T. A., Qi, J., Güveniş, A., et al. (2021) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkab048 · Cited by 55
Sinha, N., Sinha, S., Valero, C., Schäffer, A. A., Aldape, K., Litchfield, K., Chan, T. A., Morris, L. G. T., & Ruppin, E. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2542 · Cited by 54
Wen, Q., Yang, Z., Zhu, J., Qiu, Q., Dai, H., Feng, A., & Xing, L. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s261068 · Cited by 53
Yang, B., Zhou, L. Q., Zhong, J., Lv, T., Li, A., Ma, L., Zhong, J., Yin, S., Huang, L., Zhou, C., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01780-2 · Cited by 53
Liebers, N., Bruch, P., Terzer, T., Hernández-Hernández, M. V., Paramasivam, N., Fitzgerald, D., Altmann, H., Roider, T., Kolb, C., Knoll, M., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00645-5 · Cited by 53
The Double-Edged Sword—How Human Papillomaviruses Interact With Immunity in Head and Neck Cancer
Wang, H.-F., Wang, S.-S., Tang, Y.-J., Chen, Y., Zheng, M., Tang, Y.-L., & Liang, X.-H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00653 · Cited by 50
Predicting cancer immunotherapy response from gut microbiomes using machine learning models
Liang, H., Jo, J., Zhang, Z., MacGibeny, M. A., Han, J., Proctor, D. M., Taylor, M. E., Che, Y., Juneau, P. L., Apolo, A. B., et al. (2022) · Oncotarget · doi:10.18632/oncotarget.28252 · Cited by 48
Carvalho, S., Leijenaar, R. T. H., Troost, E. G. C., van Elmpt, W., Muratet, J. P., Denis, F., Ruysscher, D. D., Aerts, H. J. W. L., & Lambin, P. (2016) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(16)30042-1 · Cited by 46
Mu, W., Tunali, I., Qi, J., Schabath, M. B., & Gillies, R. J. (2020) · Radiology Artificial Intelligence · doi:10.1148/ryai.2019190063 · Cited by 45
A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non-Small-Cell Lung Cancer
Liu, C., Gong, J., Yu, H., Liu, Q., Wang, S., & Wang, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.544339 · Cited by 45
Harel, M., Lahav, C., Jacob, E., Dahan, N., Sela, I., Elon, Y., Raveh, S., Yahalom, G., Kamer, I., Zer, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004582 · Cited by 45
Li, Z.-Z., Liu, P., An, T., Yang, H., Zhang, W., & Wang, J.-X. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101065 · Cited by 41
Mu, W., Katsoulakis, E., Whelan, C. J., Gage, K. L., Schabath, M. B., & Gillies, R. J. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01375-0 · Cited by 41
Freeman, S. S., Sade-Feldman, M., Kim, J., Stewart, C., Gonye, A. L. K., Ravi, A., Arniella, M. B., Gushterova, I., LaSalle, T. J., Blaum, E. M., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100500 · Cited by 41
Self-citationYu, H., Meng, X., Chen, H., Liu, J., Gao, W., Du, L., Chen, Y., Wang, Y., Liu, X., Liu, B., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.628577 · Cited by 36
Yolchuyeva, S., Giacomazzi, E., Tonneau, M., Lamaze, F. C., Orain, M., Coulombe, F., Malo, J., Belkaïd, W., Routy, B., Joubert, P., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-38076-y · Cited by 32
Gao, X., Ma, T., Bai, S., Liu, Y., Zhang, Y., Wu, Y., Li, H., & Ye, Z. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.114 · Cited by 31
Shen, L., Fu, H., Tao, G., Liu, X., Yuan, Z., & Ye, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.591106 · Cited by 31
Fang, C., Fang, W., Xu, L., Gao, F., Hou, Y., Zou, H., Ma, Y., Moll, J. M., Yang, Y., Wang, D., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.837525 · Cited by 31
Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery
Marron, T. U., Galsky, M. D., Taouli, B., Fiel, M. I., Ward, S., Kim, E., Yankelevitz, D., Doroshow, D., Guttman-Yassky, E., Ungar, B., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01681-x · Cited by 30
Chen, H. X., Song, M., Maecker, H. T., Gnjatic, S., Patton, D. R., Lee, J. J., Adam, S. J., Moravec, R., Liu, X. S., Cerami, E. G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3241 · Cited by 29
Wang, T., Tang, Y., Pan, W., Yan, B., Hao, Y., Zeng, Y., Chen, Z., Lan, J., Zhao, S., Deng, C., et al. (2023) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000002511 · Cited by 29
Korpics, M. C., Polley, M. C., Bhave, S. R., Redler, G., Pitroda, S. P., Luke, J. J., & Chmura, S. J. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.06.026 · Cited by 26
Castello, A., Castellani, M., Florimonte, L., Urso, L., Mansi, L., & Lopci, E. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061740 · Cited by 25
Hung, S., Saiakhova, A., Faber, Z. J., Bartels, C. F., Neu, D., Bayles, I., Ojo, E. O., Hong, E. S., Pontius, W., Morton, A. R., et al. (2019) · eLife · doi:10.7554/elife.40760 · Cited by 23
Fatal Adverse Events Associated with Pembrolizumab in Cancer Patients: A Meta-Analysis
Sher, A. F., Golshani, G. M., & Wu, S. (2020) · Cancer Investigation · doi:10.1080/07357907.2020.1721521 · Cited by 23
PreCancer Atlas: Present and Future
Srivastava, S., Wagner, P. D., Hughes, S. K., & Ghosh-Janjigian, S. (2023) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-22-0435 · Cited by 23
Uncovering missed indels by leveraging unmapped reads
Hasan, M. S., Wu, X., & Zhang, L. (2019) · Scientific Reports · doi:10.1038/s41598-019-47405-z · Cited by 21
Inter-tumor heterogeneity of PD-L1 status: is it important in clinical decision making?
Suda, K., & Mitsudomi, T. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-20-1661 · Cited by 18
Ravanelli, M., Agazzi, G. M., Milanese, G., Roca, E., Silva, M., Tiseo, M., Rondi, P., Baggi, A., Ganeshan, B., Muri, M., et al. (2019) · European Journal of Radiology · doi:10.1016/j.ejrad.2019.07.019 · Cited by 16
Hes, C., & Jagoe, R. T. (2023) · BJC Reports · doi:10.1038/s44276-023-00008-8 · Cited by 16
Du, W., Hu, S., Cai, S., Wang, Y., Wu, L., Sun, D., Jiao, S., & Hu, Y. (2018) · PubMed · Cited by 14
Ladwa, R., Roberts, K. E., O’Leary, C. G., Maggacis, N., O'Byrne, K. J., & Miles, K. A. (2020) · Lung Cancer Management · doi:10.2217/lmt-2020-0002 · Cited by 14
Takahashi, N., Rajapakse, V. N., Pongor, L. S., Kumar, S., Tlemsani, C., Erwin-Cohen, R. A., Young, H. A., Hewitt, S. M., Wei, J. S., Khan, J. I., et al. (2020) · Molecular Case Studies · doi:10.1101/mcs.a005678 · Cited by 8
Cited by
The hallmarks of cancer immune evasion
Galassi, C., Chan, T. A., Vitale, I., & Galluzzi, L. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.010 · Cited by 565
Lactate and lactylation in cancer
Chen, J., Huang, Z., Chen, Y., Tian, H., Chai, P., Shen, Y., Yao, Y., Xu, S., Ge, S., & Jia, R. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02082-x · Cited by 477
Metadata
- Authors
- Holder, A. M., Dedeilia, A., Sierra-Davidson, K., Cohen, S., Liu, D., Parikh, A., & Boland, G. M.
- Venue
- Nature Reviews Cancer
- Published
- 2024-06-12
- Volume
- 24
- Issue
- 7
- Pages
- 498-512
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W4399578568
- Cited by
- 298
- References
- 250
- FWCI
- 24.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.